MedTrace Logo

MyLeukoMAP™ Genomic Survival Prediction Assay Pivotal Clinical Study

NCT05258942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-10-27

No results posted yet for this study

Summary

The MyLeukoMAP™ Pivotal Clinical Study will assess the accuracy of MyLeukoMAP™, a new molecular blood test, performed within 30 days before scheduled surgical / interventional therapies for Heart Failure, to determine its effectiveness in improving clinical decision support by providing a quantitative prediction of low, indeterminate, or high risk of death one year after surgical / interventional therapies that is not identified by current diagnostic tools.

Conditions

Interventions

OTHER

Observational

Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.

Sponsors & Collaborators

  • LeukoLifeDx Inc

    lead INDUSTRY

Principal Investigators

  • Megan Kamath, MD · University California Los Angeles

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-06-30
Completion
2023-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258942 on ClinicalTrials.gov